BENDROFLUMETHIAZIDE ( DrugBank: Bendroflumethiazide )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 1 |
67. Polycystic kidney disease
Clinical trials : 216 / Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-003182-16-GB (EUCTR) | 26/08/2005 | 29/07/2005 | Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs. | Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs. | Polycystic kidney disease | Trade Name: CARDURA Product Name: DOXAZOSIN Trade Name: MONOCOR Product Name: BISOPROLOL Trade Name: ZESTRIL Product Name: LISINOPRIL Trade Name: ISTIN Product Name: AMLODIPINE Trade Name: AMIAS Product Name: CANDESARTAN Trade Name: APRINOX Product Name: BENDROFLUMETHIAZIDE | Addenbrooke's Hospital Trust | NULL | Not Recruiting | Female: yes Male: yes | 42 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |